Lifecore Biomedical Funding Round

1/9/2023

Venture Equity

$38,750,000

Undisclosed

The Company expects to use the proceeds to support its working capital requirements and help address strong demand it is experiencing for sterile injectable pharmaceutical products while it pursues the final phases of its divestment process of non-CDMO assets, as well as for capital expenditures, repayment of the Company's indebtedness and general corporate purposes. The Company also announced the amendment of its credit facilities to provide for increased overall liquidity and amended financial covenants to allow Lifecore to achieve its growth potential.

Private & Independent

Biopharmaceutical

3515 Lyman Boulevard
Chaska, MN 55318
USA

Developer and manufacturer of mixtures and products composed of the biopolymer hyaluronan used in regenerative applications to treat osteo-arthritits, ophthalmic, and cosmetic skin procedures. The company offers hyaluronan finished products, such as Lurocoat ophthalmic viscoelastic for use in ophthalmic surgical procedures of the anterior segment, including cataract extraction and intraocular lens implantation; Ortholure orthopedic viscosupplement for pain and restricted mobility due to degenerative and traumatic changes in synovial joints, such as the knee; and dermal hydration products.